Researchers led by Université de Montréal pathology and cell-biology professor Marc Therrien have identified major structural changes that enable the BRAF protein to escape control and mimic its ...

First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated ...

NEW YORK, May 30, 2025--Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI ...

Background: Plixorafenib (FORE8394; PLX8394) is a novel, oral, small-molecule BRAF inhibitor highly selective for BRAF V600 monomers and BRAF-containing dimers. Plixorafenib binding disrupts RAF ...

Methods: This multicenter, open-label, two-part study enrolled adult pts with advanced BRAF V600-mutated solid tumors, including those with recurrent or metastatic solid tumors or primary CNS tumors.

Despite the high unmet need in BRAF V600E-mutant mCRC, prior to December 20, 2024, there were no approved biomarker-driven therapies specifically indicated for people with previously untreated BRAF ...

Pfizer’s BRAFTOVI ® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer . Pivotal results from the Phase 3 BREAKWATER trial ...

To put it simply, the Breakwater results are “the first promising survival outcomes ever reported for BRAF-mutant metastatic colorectal cancer in the first-line setting, representing a practice ...

Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in the body.

NU MOA's Carl Cholo Ahayao Melicor was the highest scorer with a 84.85% result, while two other NU MOA graduates—Jawaher Panda Aguam and Sharina Saliendra Uy—achieved the second and third highest ...

Authors and Disclosures. Marco Gessi *1 & Torsten Pietsch 1 1 Institute of Neuropathology, University of Bonn Medical Center, Sigmund-Freud-Strasse 25, D-53105, Bonn, Germany. Financial ...